COMy 2019

The 2019 World Congress on Controversies in Multiple Myeloma (COMy) was held in Paris, France on May 16–18. Experts in the field came together to discuss and debate the latest controversies in the field.

6:41
Supportive care and prophylaxis of the side effects of myeloma drugs
Heinz Ludwig
2:44
Second interim analysis of the EMN02 trial
Michele Cavo
1:11
Treatment options for relapsed myeloma: assessing the need for auto-SCT
Inger Nijhof
1:25
Coupling imaging and molecular techniques to determine MRD in MM
Elena Zamagni
2:24
MRD and outcome after transplantation
Bruno Paiva
2:52
Need for myeloma trials comparing new agents with auto-SCT
Inger Nijhof
1:28
Enhancing immune response in multiple myeloma
Sagar Lonial
2:40
Huge potential for CAR-T therapy in myeloma
Andrew Yee
1:58
With new treatment options in myeloma, is auto-SCT still necessary?
Inger Nijhof
2:54
What is the future for myeloma clinical trials?
Mohamad Mohty
1:20
Beyond KarMMa-2: agents targeting BCMA in MM
Andrew Yee
1:34
BCMA-targeting CAR-T: lessons moving forward
Sagar Lonial
3:10
LYRA findings: frontline CyBorD-Dara for myeloma
Michael O’Dwyer
1:47
International Myeloma Workshop (IMW) 2019
Kenneth Anderson
2:04
Lenalidomide for smoldering myeloma
Vincent Rajkumar
2:10
Proteasome inhibitors-based combinations for elderly MM
Maria-Victoria Mateos
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals